A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases

NCT02639260 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

NIH

Sponsor class

Conditions

Kidney Disease

Interventions

DRUG: N-acetyl D-mannosamine

Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)